Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 312

1.

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.

Lancet. 2013 Jan 12;381(9861):125-32. doi: 10.1016/S0140-6736(12)61134-9. Epub 2012 Nov 14. Erratum in: Lancet. 2013 Jan 12;381(9861):116.

PMID:
23158522
2.

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S.

Lancet Oncol. 2014 Dec;15(13):1513-20. doi: 10.1016/S1470-2045(14)70489-9. Epub 2014 Nov 10.

PMID:
25456370
3.

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN.

N Engl J Med. 2010 Nov 4;363(19):1801-11. doi: 10.1056/NEJMoa1001671.

4.

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.

Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K.

Lancet. 2013 Mar 9;381(9869):817-24.

PMID:
23312829
5.

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.

Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher T, Stein K, Berkowitz N, Bissler JJ, Franz DN.

Nephrol Dial Transplant. 2014 Jun;29(6):1203-10. doi: 10.1093/ndt/gfu013. Epub 2014 Apr 11.

6.

Rapamycin and rapalogs for tuberous sclerosis complex.

Sasongko TH, Ismail NF, Zabidi-Hussin Z.

Cochrane Database Syst Rev. 2016 Jul 13;7:CD011272. doi: 10.1002/14651858.CD011272.pub2. Review.

PMID:
27409709
7.

Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Józwiak S, Stein K, Kotulska K.

Future Oncol. 2012 Dec;8(12):1515-23. doi: 10.2217/fon.12.146. Review.

PMID:
23231513
8.

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.

French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN.

Lancet. 2016 Oct 29;388(10056):2153-2163. doi: 10.1016/S0140-6736(16)31419-2. Epub 2016 Sep 6.

9.

EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Fogarasi A, De Waele L, Bartalini G, Jozwiak S, Laforgia N, Verhelst H, Petrak B, Pedespan JM, Witt O, Castellana R, Crippa S, Gislimberti G, Gyorsok Z.

BMC Neurol. 2016 Aug 8;16:126. doi: 10.1186/s12883-016-0658-4.

10.

Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczyński D, Kmieć T, Łojszczyk B, Dunin-Wąsowicz D, Jóźwiak S.

Eur J Paediatr Neurol. 2013 Sep;17(5):479-85. doi: 10.1016/j.ejpn.2013.03.002. Epub 2013 Apr 6.

PMID:
23567018
11.

Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.

Kotulska K, Borkowska J, Roszkowski M, Mandera M, Daszkiewicz P, Drabik K, Jurkiewicz E, Larysz-Brysz M, Nowak K, Grajkowska W, Domańska-Pakieła D, Jóźwiak S.

Pediatr Neurol. 2014 Apr;50(4):307-12. doi: 10.1016/j.pediatrneurol.2013.12.004. Epub 2013 Dec 10.

PMID:
24507694
12.

Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012.

Roth J, Roach ES, Bartels U, Jóźwiak S, Koenig MK, Weiner HL, Franz DN, Wang HZ.

Pediatr Neurol. 2013 Dec;49(6):439-44. doi: 10.1016/j.pediatrneurol.2013.08.017. Epub 2013 Oct 15.

13.

Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Curran MP.

Paediatr Drugs. 2012 Feb 1;14(1):51-60. doi: 10.2165/11207730-000000000-00000. Review.

PMID:
22136276
14.

[Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].

Mateos-González ME, López-Laso E, Vicente-Rueda J, Camino-León R, Fernández-Ramos JA, Baena-Gómez MA, Peña-Rosa MJ.

Rev Neurol. 2014 Dec 1;59(11):497-502. Spanish.

15.

Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.

Trelinska J, Dachowska I, Kotulska K, Baranska D, Fendler W, Jozwiak S, Mlynarski W.

Pediatr Blood Cancer. 2015 Apr;62(4):616-21. doi: 10.1002/pbc.25368. Epub 2015 Jan 3.

PMID:
25557360
16.

Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex.

Fukumura S, Watanabe T, Takayama R, Minagawa K, Tsutsumi H.

J Child Neurol. 2015 Aug;30(9):1192-5. doi: 10.1177/0883073814544703. Epub 2014 Aug 19.

PMID:
25143481
17.

Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.

Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA.

J Pediatr. 2014 May;164(5):1195-200. doi: 10.1016/j.jpeds.2013.12.053. Epub 2014 Feb 8.

PMID:
24518170
18.

Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.

Cheng S, Hawkins C, Taylor MD, Bartels U.

Pediatr Neurol. 2015 Sep;53(3):238-242.e1. doi: 10.1016/j.pediatrneurol.2015.05.020. Epub 2015 Jun 14.

PMID:
26173783
19.

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley K, Berkowitz N, Miao S, Peyrard S, Krueger DA.

Ann Neurol. 2015 Dec;78(6):929-38. doi: 10.1002/ana.24523. Epub 2015 Nov 9.

20.

The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey.

Skalicky AM, Rentz AM, Liu Z, Wheless JW, Pelletier CL, Dunn DW, Frost MD, Nakagawa J, Magestro M, Prestifilippo J, Pashos C.

J Child Neurol. 2015 Apr;30(5):563-9. doi: 10.1177/0883073814523318. Epub 2014 Mar 24.

PMID:
24667738

Supplemental Content

Support Center